These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 26806184)

  • 21. Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
    Minhas D; Nidhaan A; Husni ME
    Rheum Dis Clin North Am; 2023 Feb; 49(1):179-191. PubMed ID: 36424024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
    Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs.
    Niculescu L; Li C; Huang J; Mallen S
    Curr Med Res Opin; 2009 Mar; 25(3):729-40. PubMed ID: 19210159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent developments in the treatment of osteoarthritis with NSAIDs.
    Argoff CE
    Curr Med Res Opin; 2011 Jul; 27(7):1315-27. PubMed ID: 21561395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of the cardiovascular safety of COXIBs compared to NSAIDS.
    Moodley I
    Cardiovasc J Afr; 2008; 19(2):102-7. PubMed ID: 18516356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
    van Walsem A; Pandhi S; Nixon RM; Guyot P; Karabis A; Moore RA
    Arthritis Res Ther; 2015 Mar; 17(1):66. PubMed ID: 25879879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ; Figgitt DP
    Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    Reicin AS; Shapiro D; Sperling RS; Barr E; Yu Q
    Am J Cardiol; 2002 Jan; 89(2):204-9. PubMed ID: 11792343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
    Lisse JR; Perlman M; Johansson G; Shoemaker JR; Schechtman J; Skalky CS; Dixon ME; Polis AB; Mollen AJ; Geba GP;
    Ann Intern Med; 2003 Oct; 139(7):539-46. PubMed ID: 14530224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism, and hip fractures among patients with osteoarthritis: a population-based study.
    Li L; Marozoff S; Lu N; Xie H; Kopec JA; Cibere J; Esdaile JM; Aviña-Zubieta JA
    Arthritis Res Ther; 2022 Apr; 24(1):85. PubMed ID: 35410440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
    McCormack PL
    Drugs; 2011 Dec; 71(18):2457-89. PubMed ID: 22141388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
    Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
    MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical use and pharmacological properties of selective COX-2 inhibitors.
    Shi S; Klotz U
    Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.
    Latimer N; Lord J; Grant RL; O'Mahony R; Dickson J; Conaghan PG
    Pharmacoeconomics; 2011 Mar; 29(3):225-37. PubMed ID: 21062104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
    Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
    Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pain management today - what have we learned?
    Langford RM
    Clin Rheumatol; 2006; 25 Suppl 1():S2-8. PubMed ID: 16741780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.